Amgen Discounting Aranesp After Medicare Reimbursement Cut
Executive Summary
Amgen is discounting Aranesp (darbepoetin alfa) to hospital customers as a result of cuts in Medicare reimbursement, the company said during a Jan. 23 earnings call
You may also be interested in...
J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13
J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call